BELLEVUE GROUP AG
Q3 2026 Form 13-F
KUESNACHT
CIK 0001674546
· Institutional investment manager
Consolidated report · includes
2 managers
since Q1 2020
$4.8B Reported Value Total
Reported value
$4.8B
Quarter over quarter
+2.0%
Holdings
154
Top-10 concentration
47.1%
Filing Structure
Reports holdings for
- BB BIOTECH AG · File #028-06964 · since Q1 2020
- Bellevue Asset Management AG · File #028-16892 · since Q1 2020
- Bellevue Asset Management UK Ltd · File #028-20408 · Q1 2024 – Q4 2025
- BB Biotech AG (not a 13F filer in our records) · File #28-06964 · Q2 2019 – Q3 2024 · declared by one filing
- Bellevue Asset Management AG (not a 13F filer in our records) · File #28-16892 · Q1 2016 – Q3 2024 · declared by one filing
- Bellevue Asset Management (UK) Ltd. (not a 13F filer in our records) · File #28-20408 · Q4 2020 – Q3 2024 · declared by one filing
- Bellevue Asset Management (UK) Ltd. (not a 13F filer in our records) · Q3 2020 – Q3 2020 · declared by one filing
- Biotech Target N V (not a 13F filer in our records) · File #28-11189 · Q2 2019 – Q2 2019 · declared by one filing
- Biotech Invest N V (not a 13F filer in our records) · File #28-11191 · Q2 2019 – Q2 2019 · declared by one filing
- Biotech Focus N V (not a 13F filer in our records) · File #28-11193 · Q2 2019 – Q2 2019 · declared by one filing
- Biotech Growth N V (not a 13F filer in our records) · File #28-11194 · Q2 2019 – Q2 2019 · declared by one filing
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Christoph Eisenring / Stefano Montalbano
Head Legal & Compliance / CFO
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $4.8B |
| Positions | 154 |
| Change in reported value | +1.4% |
| New positions | 25 |
| Exited positions | 19 |
| Position turnover | 25.4% |
| Top-10 concentration | 47.1% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
154 | $4.8B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
148 | $4.8B |
|
Q1 2026 13F
Filed May 15, 2026
|
155 | $4.2B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
176 | $5.3B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
148 | $4.8B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
142 | $4.5B |
|
Q1 2025 13F
Filed May 14, 2025
|
148 | $4.5B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
160 | $5.2B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
162 | $6.2B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
166 | $6.2B |
|
Q1 2024 13F
Filed May 15, 2024
|
169 | $6.6B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
161 | $6.5B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
154 | $6.2B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
156 | $7.0B |
|
Q1 2023 13F
Filed May 15, 2023
|
159 | $6.9B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
171 | $7.5B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
176 | $7.0B |
|
Q2 2022 13F
Filed Aug 11, 2022
|
172 | $7.1B |
|
Q1 2022 13F
Filed May 13, 2022
|
177 | $8.6B |
|
Q4 2021 13F
Filed Feb 10, 2022
|
191 | $9.7B |
23 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | AMGN AMGEN INC | $363.2M | 7.54% |
| 2 | GILD GILEAD SCIENCES INC | $320.6M | 6.65% |
| 3 | VRTX VERTEX PHARMACEUTICALS INC | $302.5M | 6.28% |
| 4 | ARGX ARGENX SE | $278.6M | 5.78% |
| 5 | REGN REGENERON PHARMACEUTICALS | $212.0M | 4.4% |
| 6 | RVMD REVOLUTION MEDICINES INC | $205.0M | 4.25% |
| 7 | INSM INSMED INC | $172.1M | 3.57% |
| 8 | VRDN VIRIDIAN THERAPEUTICS INC | $146.4M | 3.04% |
| 9 | ORKA ORUKA THERAPEUTICS INC | $136.7M | 2.84% |
| 10 | BIIB BIOGEN INC | $135.1M | 2.8% |
| 11 | SRRK SCHOLAR ROCK HLDG CORP | $134.7M | 2.79% |
| 12 | PCVX VAXCYTE INC | $132.1M | 2.74% |
| 13 | RLAY RELAY THERAPEUTICS INC | $111.7M | 2.32% |
| 14 | ABT ABBOTT LABORATORIES | $103.6M | 2.15% |
| 15 | UTHR UNITED THERAPEUTICS CORP DEL | $101.0M | 2.1% |
| 16 | ISRG INTUITIVE SURGICAL INC | $100.8M | 2.09% |
| 17 | MDT MEDTRONIC PLC | $90.0M | 1.87% |
| 18 | BBIO BRIDGEBIO PHARMA INC | $78.7M | 1.63% |
| 19 | IMCR IMMUNOCORE HLDGS PLC | $68.6M | 1.42% |
| 20 | ELVN ENLIVEN THERAPEUTICS INC | $67.3M | 1.4% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.